BelHealth Completes Acquisition of Skila

June 20, 2011 - PRLog -- BelHealth Investment Partners (“BelHealth”), a healthcare-focused private equity buyout fund, announced today that it has completed its acquisition of Skila, Sela2, Inc. (“Skila”).

Skila provides the healthcare industry with fully managed solutions that allow life science customers to focus on core business processes and engagement management across the lifecycle of product launches. Skila’s award-winning solutions include a proven knowledge-management methodology that incorporates change management and organizational culture with configurable Intelligration® technology that integrates and maximizes the use of existing systems, public data and stakeholder knowledge. Skila’s robust product launch and key opinion leader (KOL) management solutions offer continuous knowledge and user support that help organizations manage people, processes, knowledge and change over time.

According to Skila Vice Chairman Moish Tov, “We are excited about being the first investment within the BelHealth fund and the strategic fit with Skila’s culture and vision. I am very pleased and proud that Simon Mason was chosen by BelHealth to be the new President, and I am confident that he will lead Skila to the next level. The transaction will help us to grow our impressive product launch management solutions and to continue to position Skila as the leader in KOL management.”

Simon Mason, the newly promoted President and Chief Operating Officer of Skila, said “The acquisition provides Skila with the resources that will propel us forward in the market place. Skila has emerged stronger than ever as we look forward to viral growth and bottom-line value that provide our clients with an even greater ability to transform critical and interconnecting information into actionable and accountable knowledge.”

Dennis Drislane, Chairman of the Operating Committee for BelHealth and an incoming Board Member of Skila, said “As the first member of the BelHealth portfolio, Skila enables us to create the foundation to achieve superior returns by investing in businesses that provide true value and increased impact for clients in the life sciences industry. With Skila as the cornerstone of BelHealth’s platform in pharmaceutical services, we plan to expand aggressively through organic growth and acquisitions. I’d like to take this opportunity to welcome the Skila employees from all over the globe, including the United States, Ukraine, United Kingdom and Israel.”

# # #

Skila, a BelHealth Investment Partner company, is a global technology and services company specializing in product launch lifecycle management and engagment / relationship management solutions for the healthcare industry. Skila’s solutions address the needs of global marketing, medical, market access, executive and alliance management teams that include a unique methodology, robust technology and continuous services for effectively managing global product launches, key opinion leader relationships, market access / managed care, business performance, competitive intelligence, and key partnerships and alliances. Skila’s solutions have been deployed in 61 countries, supporting numerous global brands and more than 10 million user interactions. Skila’s long-standing commitment and understanding of customers’ needs has resulted in the long-term growth and adoption of our methodology, technology and continuous services as the business platform of choice for many of our clients.